# Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients

> **NCT02182479** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 631 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Berodual® via Respimat®, high dose
- **DRUG:** Berodual® via Respimat®, low dose
- **DRUG:** Berodual® via MDI, high dose
- **DRUG:** Placebo Respimat®
- **DRUG:** Placebo MDI

## Key facts

- **NCT ID:** NCT02182479
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-04
- **Primary completion:** 1999-06
- **Final completion:** —
- **Target enrollment:** 631 (ACTUAL)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182479, "Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02182479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*